丙型肝炎病毒（hepatitis C virus，HCV）是一種高度變異的正鏈RNA黃病毒，具有慢性轉(zhuǎn)化率高、病變率高等特征。有研究表明，NS3/NS4A多功能蛋白酶是HCV復(fù)制所必須的，因而NS3/NS4A蛋白酶抑制劑在HCV治療中的意義備受關(guān)注。替拉瑞韋（Telaprevir）是一種可逆的HCV NS3/NS4A蛋白酶抑制劑，動物試驗和臨床試驗都表明它可以有效地直接攻擊HCV并阻斷其復(fù)制，對HCV的抑制作用持久，將成為丙型肝炎病毒的新型治療藥物。

Hepatitis C virus (HCV) is a highly variable positive-strand RNA flavivirus, and has the characteristics of chronic high conversion and pathologic change. There are evidences shown that NS3/NS4A protease activity is essential for viral replication, thus the therapeutic significance of inhibiting the HCV protease NS3/NS4A has been widely concerned. Telaprevir, an ig administered, reversible, and peptidomimetic inhibitor of the HCV protease NS3/NS4A, has been proved to be effective for attacking HCV and breaking viral replication both in animal experiments and clinical trials. It is expected to become a new drug for treatment of HCV.